|
|
Prepublished online as a Blood First Edition Paper on March 13, 2003; DOI 10.1182/blood-2002-09-2846.
 Previous Article | Table of Contents | Next Article 
Blood, 1 July 2003, Vol. 102, No. 1, pp. 69-77
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
Linda Mileshkin,
James J. Biagi,
Paul Mitchell,
Craig Underhill,
Andrew Grigg,
Richard Bell,
Joe McKendrick,
Peter Briggs,
John F. Seymour,
Kate Lillie,
Jennifer G. Smith,
Jerome B. Zeldis, and
H. Miles Prince
From the Department of Haematology and the Statistical Centre, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Ludwig Oncology Department, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia; Border Medical Oncology, Albury, Victoria, Australia; Department of Haematology, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Andrew Love Cancer Centre, The Geelong Hospital, Geelong, Victoria, Australia; Oncology Department, Box Hill Hospital, Box Hill, Victoria, Australia; Oncology Department, Monash Medical Centre, Clayton, Victoria, Australia; and Celgene, Warren, NJ.
Relapsed or refractory multiple myeloma has a poor outlook. Some patients respond to thalidomide; however, criteria for predicting response have not been conclusively identified. We initiated a prospective multicenter phase 2 trial in patients with relapsed/refractory myeloma using thalidomide up to the maximum dose, 800 mg/d. Interferon- -2B (1.5-3.0 x 106 U, subcutaneously, 3 times per week) was added at week 12 if disease was responsive or stable. Patients intolerant of interferon continued thalidomide alone. Thalidomide with or without interferon was continued until disease progression. Objectives were to determine toxicity, response rate (RR), progression-free survival (PFS), and overall survival (OS) and to elucidate relevant prognostic factors. We enrolled 75 patients, with median age 64 years (range, 36-83 years). Median individual maximum-tolerated dose of thalidomide was 600 mg/d; 41% reached 800 mg/d. Overall RR was 28%, and 55% stable disease (SD). The only predictor for response was age 65 years or younger (38% versus 17%; P = .043). At 18 months median follow-up, the actuarial median PFS and OS were 5.5 and 14.6 months, respectively. Multivariate analysis for OS demonstrated age exceeding 65 years (median, 9.2 months versus longer than 26 months; P = .011), raised serum lactate dehydrogenase (P = .002), and raised serum creatinine (P = .007) predicted inferior outcomes. Nineteen patients received interferon. Ten discontinued owing to toxicity. Four of 12 patients who received interferon for longer than 4 weeks were converted from SD to partial response. Our findings confirm substantial activity of thalidomide in relapsed/refractory myeloma. Interferon may improve response in selected patients, but is often not tolerated. The inferior outcome demonstrated in those with the identified prognostic factors is important in planning management for such patients. (Blood. 2003;102:69-77)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Thalidomide, age, and future use in multiple myeloma
- Mohamad A. Hussein
Blood 2003 102: 2-3.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
N. D. Yildirim, M. Ayer, R. D. Kucukkaya, N. Alpay, O. Mete, M. N. Yenerel, A. S. Yavuz, and M. Nalcaci
Leukocytoclastic Vasculitis due to Thalidomide in Multiple Myeloma
Jpn. J. Clin. Oncol.,
September 1, 2007;
37(9):
704 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mileshkin, D. Honemann, P. Gambell, M. Trivett, Y. Hayakawa, M. Smyth, V. Beshay, D. Ritchie, P. Simmons, A. D. Milner, et al.
Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome
Haematologica,
August 1, 2007;
92(8):
1075 - 1082.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson
New Drugs for Myeloma
Oncologist,
June 1, 2007;
12(6):
664 - 689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mileshkin, R. Stark, B. Day, J. F. Seymour, J. B. Zeldis, and H. M. Prince
Development of Neuropathy in Patients With Myeloma Treated With Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring
J. Clin. Oncol.,
September 20, 2006;
24(27):
4507 - 4514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Zonder
Thrombotic Complications of Myeloma Therapy
Hematology,
January 1, 2006;
2006(1):
348 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Hiddemann, M. Kneba, M. Dreyling, N. Schmitz, E. Lengfelder, R. Schmits, M. Reiser, B. Metzner, H. Harder, S. Hegewisch-Becker, et al.
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Blood,
December 1, 2005;
106(12):
3725 - 3732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Mileshkin, P. Gambell, V. Beshay, Y. Hayakawa, M. Smyth, M. Trivett, P. J. Simmons, A. Milner, J. B. Zeldis, and M. Prince
Increased Marrow CD57+ Cytotoxic T Cells Is a Powerful Prognostic Marker for Survival in Patients with Relapsed Multiple Myeloma (MM) Receiving Thalidomide.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
3486 - 3486.
[Abstract]
|
|
|
|
|
|
|
M. Duyvendak, M. Naunton, B. J Kingma, and J. R. Brouwers
Thalidomide-Associated Thrombocytopenia
Ann. Pharmacother.,
November 1, 2005;
39(11):
1936 - 1939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S. V. Rajkumar, T. Hideshima, H. Xiao, D. Esseltine, et al.
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
Blood,
November 1, 2005;
106(9):
2977 - 2981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Saunders
Overview of drug therapy for multiple myeloma
Journal of Oncology Pharmacy Practice,
September 1, 2005;
11(3):
83 - 100.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H M. Prince, L. Mileshkin, A. Roberts, V. Ganju, C. Underhill, J. Catalano, R. Bell, J. F. Seymour, D. Westerman, P. J. Simmons, et al.
A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma
Clin. Cancer Res.,
August 1, 2005;
11(15):
5504 - 5514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-Y. Pei, Y. Dai, M. Rahmani, W. Li, P. Dent, and S. Grant
The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01-Induced Apoptosis in Human Multiple Myeloma Cells
Clin. Cancer Res.,
June 15, 2005;
11(12):
4589 - 4600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. W. B. Jeffes, J. G. Zhang, N. Hoa, A. Petkar, C. Delgado, S. Chong, A. Obenaus, R. Sanchez, S. Khalaghizadeh, T. Khomenko, et al.
Antiangiogenic Drugs Synergize with a Membrane Macrophage Colony-Stimulating Factor-Based Tumor Vaccine to Therapeutically Treat Rats with an Established Malignant Intracranial Glioma
J. Immunol.,
March 1, 2005;
174(5):
2533 - 2543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-Y. Pei, Y. Dai, and S. Grant
The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism
Mol. Cancer Ther.,
December 1, 2004;
3(12):
1513 - 1524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chintagumpala, S. M. Blaney, L. R. Bomgaars, A. Aleksic, J. F. Kuttesch, R. A. Klenke, and S. L. Berg
Phase I and Pharmacokinetic Study of Thalidomide With Carboplatin in Children With Cancer
J. Clin. Oncol.,
November 1, 2004;
22(21):
4394 - 4400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-Y. Pei, Y. Dai, and S. Grant
Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors
Clin. Cancer Res.,
June 1, 2004;
10(11):
3839 - 3852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Dai, X.-Y. Pei, M. Rahmani, D. H. Conrad, P. Dent, and S. Grant
Interruption of the NF-{kappa}B pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells
Blood,
April 1, 2004;
103(7):
2761 - 2770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Dimopoulos, A. Anagnostopoulos, and D. Weber
Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives
J. Clin. Oncol.,
December 1, 2003;
21(23):
4444 - 4454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
